AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8007616 — intervention group
Group type: EXPERIMENTAL
Intervention: Subfascial lymphovenous anastomoses (LVA) operation
Number of subjects: 62
Study 2260146 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk approach with drugs to reduce risk factors in individuals with high levels
Number of subjects: 0
Study 2260146 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass approach with lifestyle modifications for the general population
Number of subjects: 0
Study 6779673 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion of 7.8 microgram . kg‐1 . mn‐1 (Group I)
Number of subjects: 6
Study 6779673 — intervention group
Group type: COMPARATOR
Intervention: No vasodilator drug (Group II)
Number of subjects: 6
Study 31813763 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medicines review intervention (medicines education session, medicines optimisation session)
Number of subjects: 30
Study 31813763 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medicines review intervention
Number of subjects: 30
Study 30507360 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome in normal weight patients (BMI 18.5-24.9 kg/m2)
Number of subjects: 3729
Study 30507360 — intervention group
Group type: COMPARATOR
Intervention: Metabolic syndrome in overweight patients (BMI 25-29.9 kg/m2)
Number of subjects: 3729
Study 30507360 — intervention group
Group type: COMPARATOR
Intervention: Metabolic syndrome in obese patients (BMI ≥30 kg/m2)
Number of subjects: 3729
Study 28217871 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 551
Study 28217871 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg
Number of subjects: 551
Study 28217871 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 551
Study 28217871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551
Study 25526271 — intervention group
Group type: EXPERIMENTAL
Intervention: Minipterional craniotomy (MPT)
Number of subjects: 58
Study 25526271 — intervention group
Group type: COMPARATOR
Intervention: Classic pterional craniotomy (PT)
Number of subjects: 58
Study 24106745 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning
Number of subjects: 102
Study 24106745 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol (Control)
Number of subjects: 102
Study 21212059 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels
Number of subjects: 752
Study 21212059 — intervention group
Group type: COMPARATOR
Intervention: Control group (polyp-free individuals)
Number of subjects: 752
Study 19186961 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive ceramic filler (BCF)
Number of subjects: 13
Study 19186961 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 13
Study 19186961 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 13
Study 17893575 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 70
Study 17893575 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 70
Study 15065953 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Behavioral Couple Therapy (IBCT)
Number of subjects: 134
Study 15065953 — intervention group
Group type: COMPARATOR
Intervention: Traditional Behavioral Couple Therapy (TBCT)
Number of subjects: 134
Study 11837466 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2 grams elemental calcium daily from 20 weeks of gestation to delivery)
Number of subjects: 100
Study 11837466 — intervention group
Group type: COMPARATOR
Intervention: No calcium supplementation (control group)
Number of subjects: 100
Study 11837466 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 100
Study 9497178 — intervention group
Group type: COMPARATOR
Intervention: 0 g psyllium seed husk (control)
Number of subjects: 286
Study 7799829 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 + NETA
Number of subjects: 143
Study 7799829 — intervention group
Group type: EXPERIMENTAL
Intervention: E2V + LNG
Number of subjects: 143
Study 7799829 — intervention group
Group type: EXPERIMENTAL
Intervention: E2V + MPA
Number of subjects: 143
Study 7799829 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 + DG
Number of subjects: 143
Study 7799829 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 143
Study 2529108 — intervention group
Group type: EXPERIMENTAL
Intervention: GR 38032F (0.15 mg/kg)
Number of subjects: 10
Study 1068646 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis with oral nonabsorbed antibiotics and a nasal antibiotic ointment
Number of subjects: 36
Study 1068646 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient isolation and suppression of gut flora
Number of subjects: 36
Study 30528592 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebola vaccine trial participants
Number of subjects: 88
Study 30528592 — intervention group
Group type: COMPARATOR
Intervention: Adjuvanted seasonal influenza vaccine trial participants
Number of subjects: 88
Study 26621633 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-reduced infant formula with alpha-lactalbumin-enriched whey and free tryptophan and phenylalanine (IF)
Number of subjects: 213
Study 26621633 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric standard formula without free amino acids (CF)
Number of subjects: 213
Study 26621633 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed infants (BF)
Number of subjects: 213
Study 25408273 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-balloon catheter
Number of subjects: 155
Study 25408273 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone vaginal insert
Number of subjects: 155
Study 25408273 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 155
Study 23799922 — intervention group
Group type: EXPERIMENTAL
Intervention: LAN 90 mg
Number of subjects: 132
Study 23799922 — intervention group
Group type: EXPERIMENTAL
Intervention: LAN 120 mg
Number of subjects: 132
Study 23799922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 21406998 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) 60-100 mg
Number of subjects: 502
Study 21406998 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 502
Study 21406998 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 502
Study 19746429 — intervention group
Group type: EXPERIMENTAL
Intervention: 940 nm diode laser
Number of subjects: 24
Study 19746429 — intervention group
Group type: COMPARATOR
Intervention: 532 nm diode laser
Number of subjects: 24
Study 17089234 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 46
Study 17089234 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 46
Study 14734517 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective adenosine A2A receptor agonist binodenoson (various doses)
Number of subjects: 240
Study 14734517 — intervention group
Group type: COMPARATOR
Intervention: Adenosine
Number of subjects: 240
Study 11150976 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with complete nerve lesions
Number of subjects: 32
Study 11150976 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 32
Study 9212962 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Myocardial Management (IMM)
Number of subjects: 262
Study 9212962 — intervention group
Group type: COMPARATOR
Intervention: Non-IMM
Number of subjects: 262
Study 8021328 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical psychopharmacology curriculum
Number of subjects: 0
Study 8021328 — intervention group
Group type: COMPARATOR
Intervention: Teaching effectiveness and resident acceptance of the program
Number of subjects: 0
Study 3482470 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 in different vehicles for cervical ripening and labor induction
Number of subjects: 0
Study 3482470 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31403574 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward sled towing at 55% reduction of individual's maximal velocity (rVelmean)
Number of subjects: 18
Study 31403574 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward sled towing at 35% reduction of individual's maximal velocity (rVelmean)
Number of subjects: 18
Study 31403574 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward sled towing at 55% reduction of individual's maximal velocity (rVelmean)
Number of subjects: 18
Study 31403574 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward sled towing at 35% reduction of individual's maximal velocity (rVelmean)
Number of subjects: 18
Study 28722766 — intervention group
Group type: EXPERIMENTAL
Intervention: mABQ method
Number of subjects: 6236
Study 28722766 — intervention group
Group type: COMPARATOR
Intervention: GSQ method
Number of subjects: 6236
Study 28722766 — intervention group
Group type: EXPERIMENTAL
Intervention: mABQ VFs
Number of subjects: 6236
Study 28722766 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 1 mABQ VFs
Number of subjects: 6236
Study 27457257 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprostene bunod 0.024%
Number of subjects: 25
Study 27457257 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 25
Study 25336668 — intervention group
Group type: EXPERIMENTAL
Intervention: CPVI + SVC-L
Number of subjects: 200
Study 25336668 — intervention group
Group type: COMPARATOR
Intervention: CPVI
Number of subjects: 200
Study 24423913 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway‐Supreme(TM)
Number of subjects: 100
Study 24423913 — intervention group
Group type: COMPARATOR
Intervention: Common laryngeal mask airway
Number of subjects: 100
Study 20839697 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless total hip replacement (THR)
Number of subjects: 250
Study 20839697 — intervention group
Group type: COMPARATOR
Intervention: Cemented total hip replacement (THR)
Number of subjects: 250
Study 20839697 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless tapered stem
Number of subjects: 250
Study 20839697 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented and cementless THR in patients younger than 65 years
Number of subjects: 250
Study 20839697 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless THR in male patients
Number of subjects: 250
Study 18422606 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 146
Study 18422606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 16841676 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenmai Injection (SI) with chemotherapy
Number of subjects: 45
Study 16841676 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 45
Study 14605733 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic, total extraperitoneal hernioplasty (TEP)
Number of subjects: 138
Study 14605733 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein hernioplasty
Number of subjects: 138
Study 11036121 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil and prednisolone
Number of subjects: 42
Study 11036121 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide and prednisolone followed by azathioprine and prednisolone
Number of subjects: 42
Study 8858271 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg N-acetylcysteine (NAC) for 4 months
Number of subjects: 0
Study 8858271 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 months
Number of subjects: 0
Study 1620143 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA
Number of subjects: 6
Study 1620143 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA methyl ester
Number of subjects: 6
Study 3844158 — intervention group
Group type: EXPERIMENTAL
Intervention: High psychosocial care
Number of subjects: 26
Study 3844158 — intervention group
Group type: COMPARATOR
Intervention: Low psychosocial care
Number of subjects: 26
Study 31272494 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglossal acupuncture
Number of subjects: 75
Study 31272494 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 75
Study 31272494 — intervention group
Group type: COMPARATOR
Intervention: Dietary recommendations
Number of subjects: 75
Study 29354929 — intervention group
Group type: EXPERIMENTAL
Intervention: Five needles therapy
Number of subjects: 210
Study 29354929 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 210
Study 25869479 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral glutamine (15 gr)
Number of subjects: 40
Study 25869479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24489648 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-related multi-component health promotion intervention (n = 129)
Number of subjects: 257
Study 24489648 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 257
Study 22229478 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg p.o.
Number of subjects: 29
Study 22229478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 20535920 — intervention group
Group type: EXPERIMENTAL
Intervention: Salviae injection and ligustrazine injection (S & L) in combination with conventional Western medical treatment
Number of subjects: 63
Study 20535920 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medical treatment
Number of subjects: 63
Study 20535920 — intervention group
Group type: EXPERIMENTAL
Intervention: Salviae injection and ligustrazine injection (S & L)
Number of subjects: 63
Study 18007992 — intervention group
Group type: EXPERIMENTAL
Intervention: Global System for Mobile Communication (GSM) exposure
Number of subjects: 176
Study 18007992 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal Mobile Telecommunications System (UMTS) exposure
Number of subjects: 176
Study 18007992 — intervention group
Group type: COMPARATOR
Intervention: GSM signal during double-blind tests
Number of subjects: 176
Study 18007992 — intervention group
Group type: EXPERIMENTAL
Intervention: UMTS signal during double-blind tests
Number of subjects: 176
Study 18007992 — intervention group
Group type: COMPARATOR
Intervention: Physiological measures (blood volume pulse, heart rate, skin conductance)
Number of subjects: 176
Study 16671427 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical intervention
Number of subjects: 0
Study 16671427 — intervention group
Group type: COMPARATOR
Intervention: Initial conservative management
Number of subjects: 0
Study 16671427 — intervention group
Group type: COMPARATOR
Intervention: IVH absent
Number of subjects: 0
Study 16671427 — intervention group
Group type: COMPARATOR
Intervention: IVH present with hydrocephalus
Number of subjects: 0
Study 12781936 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored decision aid (DA)
Number of subjects: 224
Study 12781936 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet
Number of subjects: 224
Study 11147227 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT)
Number of subjects: 0
Study 11147227 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (BMT)
Number of subjects: 0
Study 11147227 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 11147227 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic BMT
Number of subjects: 0
Study 8630464 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast antipyrine metabolism in lung cancer patients and their first degree relatives
Number of subjects: 0
Study 8630464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate antipyrine metabolism
Number of subjects: 0
Study 8630464 — intervention group
Group type: COMPARATOR
Intervention: Slow antipyrine metabolism
Number of subjects: 0
Study 1353720 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin infusion (250 micrograms/h for 96 h)
Number of subjects: 60
Study 1353720 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular Gold salts
Number of subjects: 60
Study 1353720 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold salts for 8 months with Somatostatin infusion at the fourth month
Number of subjects: 60
Study 6362368 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaine/haematoporphyrin (KH3)
Number of subjects: 500
Study 6362368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 31453640 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective Tissue Grafting (CTG)
Number of subjects: 15
Study 31453640 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR)
Number of subjects: 15
Study 30627845 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 serial mud baths within 21 days in addition to a multimodal physical rehabilitative complex treatment
Number of subjects: 81
Study 30627845 — intervention group
Group type: COMPARATOR
Intervention: Only physical rehabilitative treatment without mud baths
Number of subjects: 81
Study 27811204 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF‐15 (highest quartile)
Number of subjects: 14577
Study 26391974 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS181 (20mg) for 3 days
Number of subjects: 18
Study 26391974 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS181 (20mg) for 10 days
Number of subjects: 18
Study 26391974 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS181 (20mg) for 1 day
Number of subjects: 18
Study 23689036 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mM sucralose (SUCRA)
Number of subjects: 23
Study 23689036 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 23
Study 21988625 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive testing (retest group)
Number of subjects: 80
Study 21988625 — intervention group
Group type: COMPARATOR
Intervention: Repetitive studying (restudy group)
Number of subjects: 80
Study 19853089 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermabond skin glue
Number of subjects: 106
Study 19853089 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular sutures
Number of subjects: 106
Study 17356110 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil therapy for 3 months
Number of subjects: 14
Study 15639128 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG power spectrum data during resting conditions
Number of subjects: 57
Study 15639128 — intervention group
Group type: EXPERIMENTAL
Intervention: Recording length increased from 40 to 400 s
Number of subjects: 57
Study 15639128 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 s epochs of EEG power
Number of subjects: 57
Study 15639128 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample size increase
Number of subjects: 57
Study 11716085 — intervention group
Group type: EXPERIMENTAL
Intervention: AH26
Number of subjects: 0
Study 11716085 — intervention group
Group type: EXPERIMENTAL
Intervention: Kerr Pulp Canal Sealer
Number of subjects: 0
Study 11716085 — intervention group
Group type: EXPERIMENTAL
Intervention: Roths 801 (nonstaining)
Number of subjects: 0
Study 11716085 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealapex
Number of subjects: 0
Study 9164194 — intervention group
Group type: EXPERIMENTAL
Intervention: BEP (bleomycin, etoposide, and cisplatin)
Number of subjects: 598
Study 9164194 — intervention group
Group type: COMPARATOR
Intervention: CEB (bleomycin, etoposide, and carboplatin)
Number of subjects: 598
Study 7953038 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate community psychiatric nursing intervention
Number of subjects: 177
Study 7953038 — intervention group
Group type: COMPARATOR
Intervention: Continuing GP care
Number of subjects: 177
Study 7953038 — intervention group
Group type: COMPARATOR
Intervention: 12-week waiting-list for CPN intervention
Number of subjects: 177
Study 2892458 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg a day
Number of subjects: 16
Study 2892458 — intervention group
Group type: COMPARATOR
Intervention: Betaxolol 20 mg a day
Number of subjects: 16
Study 29600595 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral tablets
Number of subjects: 277
Study 29600595 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly vaginal ring
Number of subjects: 277
Study 29600595 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly intramuscular injections
Number of subjects: 277
Study 29600595 — intervention group
Group type: EXPERIMENTAL
Intervention: TRIO products (all forms)
Number of subjects: 277
Study 29600595 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo delivery forms (overall)
Number of subjects: 277
Study 29600595 — intervention group
Group type: EXPERIMENTAL
Intervention: Injections
Number of subjects: 277
Study 29600595 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets and rings
Number of subjects: 277
Study 29600595 — intervention group
Group type: EXPERIMENTAL
Intervention: Product-related adverse events
Number of subjects: 277
Study 27294814 — intervention group
Group type: EXPERIMENTAL
Intervention: Mozart music (Symphony No. 40 in g minor, KV 550)
Number of subjects: 60
Study 27294814 — intervention group
Group type: EXPERIMENTAL
Intervention: Strauss music
Number of subjects: 60
Study 27294814 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBA music
Number of subjects: 60
Study 27294814 — intervention group
Group type: COMPARATOR
Intervention: Silence (control group)
Number of subjects: 60
Study 24552320 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg) plus chemotherapy (cisplatin-paclitaxel or topotecan-paclitaxel)
Number of subjects: 452
Study 24552320 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (cisplatin-paclitaxel or topotecan-paclitaxel)
Number of subjects: 452
Study 23750033 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercaloric feeding (30% excess calories)
Number of subjects: 8
Study 23750033 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric feeding (matched energy expenditure)
Number of subjects: 8
Study 19914003 — intervention group
Group type: EXPERIMENTAL
Intervention: Project SUCCESS intervention group
Number of subjects: 14
Study 19914003 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14